Sirtuins family-recent development as a drug target for aging, metabolism, and age related diseases

Current Drug Targets

Volumn 14, Issue 6, 2013, Pages 666-675

  Chakraborty, Chiranjib ^a   George Priya Doss, C ^b  

^a GALGOTIAS UNIVERSITY   (India)

^b VIT UNIVERSITY   (India)

Author keywords

Age related diseases; Aging; Drug target; Metabolism; Sirtuins

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; SIRTUIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7;

AGING; ARTICLE; CALORIC RESTRICTION; CANCER RISK; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVITY; GENE LOCATION; GENE MUTATION; GENE SILENCING; HUMAN; INSULIN RESISTANCE; KIDNEY DISEASE; LONGEVITY; METABOLIC REGULATION; METABOLIC SYNDROME X; METABOLISM; MOLECULAR BIOLOGY; NONHUMAN; SURVIVAL RATE;

AGE FACTORS; ANIMALS; DRUG DISCOVERY; HUMANS; METABOLISM; MOLECULAR TARGETED THERAPY; SIRTUINS;

EID: 84878550919     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314060008     Document Type: Article

References (166)

1. Goetzl EJ. Is aging a drug target? FASEB J 2011; 25: 2509-11.
2. Hall GS. Adolescence-Its Psychology and Its Relations to Physiology, Anthropology, Sociology, Sex, Crime, Religion and Education D. Appleton and Company, New York 1904
3. Hall GS. Senescence, the last half of life, D. Appleton and Company, New York 1922.
4. Guarente L. Sirtuins, Aging, and Medicine. N Engl J Med 2011; 364: 2235-44.
5. Rodriguez-Rodero S, Fernandez-Morera JL, Menéndez-Torre E, Calvanese V, Fernández AF, Fraga MF. Aging genetics and aging. Aging Dis 2011; 2: 186-95.
6. Harman D. The aging process. Proceedings of the National Academy of Sciences 1981; 78: 7124-8.
7. Ashok BT, Ali R. The aging paradox: free radical theory of aging. Exp Gerontology 1999; 34: 293-303.
8. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, aging. Cell 2005; 120: 483-95.
9. Bokov A, Chaudhuri A, Richardson A. The role of oxidative damage and stress in aging. Mech Ageing Dev 2004; 125: 811-26.
10. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47-95.
11. Kregel KC, Zhang HJ. An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Integr Comp Physiol 2006; 292: R18-36.
12. Iqbal K, Jin SG, Pfeifer, GP, Szabo PE. Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. Proceedings of the National Academy of Sciences 2011; 108: 3642-7.
13. Bestor T, Laudano A, Mattaliano R, Ingram V. Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J Mol Biol 1988; 203: 971-83.
14. Martinowich K, Hattori D, Wu H, et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 2003; 302: 890-3.
15. Goyal, R, Reinhardt R, Jeltsch A. Accuracy of DNA methylation pattern preservation by the Dnmt1 methyltransferase. Nucleic Acids Res 2006; 34: 1182-8.
16. Holliday R. The inheritance of epigenetic defects. Science 1987; 238: 163-70.
17. Drinkwater RD, Blake TJ, Morley AA, Turner DR. Human lymphocytes aged in vivo have reduced levels of methylation in transcriptionally active and inactive DNA. Mutat Res 1989; 219: 29-37.
18. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
19. Sharma R, Nakamura A, Takahashi R, Nakamoto H, Goto S. Carbonyl modification in rat liver histones:decrease with age and increase by dietary restriction. Free Radic Biol Med 2006; 40: 1179-84.
20. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005; 102: 10604-9.
21. Bernstein BE, Kamal M, Lindblad-Toh K, et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 2005; 120: 169-81.
22. Sarg B, Koutzamani E, Helliger W, Rundquist I, Lindner HH. Postsynthetic trimethylation of histone H4 at lysine 20 in mammalian tissues is associated with aging. J Biol Chem 2002; 277: 39195-201.
23. Michishita E, McCord RA, Berber E, et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 2008; 452: 492-6.
24. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 2007; 26: 5489-504.
25. Leipe DD, Landsman D. Histone deacetylases, acetoin utilization proteins and acetylpolyamine amidohydrolases are members of an ancient protein superfamily. Nucleic Acids Res 1997; 25 (18): 3693-7.
26. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004; 73: 417-35.
27. Donmez G, Guarente L. Aging and disease: connections to sirtuins. Aging Cell 2010; 9: 285-90.
28. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 2010; 5: 253-95.
29. Tosato M, Zamboni V, Ferrini A, Cesari M. The aging process and potential interventions to extend life expectancy. Clin Interv Aging 2007; 2: 401-12.
30. Weismann A. Essays upon heredity. Oxford: Clarendon Press; 1891.
31. Medawar PB. An unsolved problem of biology. London: HK Lewis; 1952.
32. Williams GC. Pleiotropy, natural selection, and the evolution of senescence. Evolution 1957; 11: 398-411.
33. Johnson FB, Sinclair DA, Guarente L. Molecular biology of aging. Cell 1999; 96: 291-302.
34. Harman D. The free radical theory of aging. Antioxid Redox Signal 2003; 5: 557-61.
35. Klar AJ, Seymour F, Macleod K. MAR1-A regulator of the HMa and HMα locus in Saccharomyces cerevisiae. Genetics 1979; 93: 37-50.
36. Rine J, Strathern JN, Hicks JB, Herskowitz IA. suppressor of mating-type locus mutations in Saccharomyces cerevisiae: evidence for and identification of cryptic mating-type loci. Genetics 1979; 93: 877-901.
37. Schumacher A. Aging epigenetics. In: Handbook of Epigeneticsthe new molecular and medical genetics. (Editor: Trygve Tollefsbol) Elsevier. 2010. PP 405-21.
38. Shore D, Squire M, Nasmyth KA. Characterization of two genes required for the position-effect control of yeast mating-type genes. EMBO J 1984; 3: 2817-23.
39. Ivy JM, Hicks JB, Klar AJ. Map positions of yeast genes SIR1, SIR3 and SIR4. Genetics 1985; 111: 735-44.
40. Rine J, Herskowitz I. Four genes responsible for a position effect on expression from HML and HMR in Saccharomyces cerevisiae. Genetics 1987; 116: 9-22.
41. Hallows WC, Albaugh BN, Denu JM. Where in the cell is SIRT3? Functional localization of an NAD+-dependent protein deacetylase, Biochem J 2008: 411: 11-3.
42. Hursting SD, Lavigne JA, Berrigan D, Perkins, SN, Barrett JC. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med 2003: 54: 131-52.
43. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460: 587-91.
44. Kennedy BK, Austriaco NR, Jr, Zhang J, Guarente L. Mutation in the silencing gene SIR4 can delay aging in S. cerevisiae. Cell 1995; 80: 485-96.
45. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999; 13: 2570-80.
46. Rogina B, Helfand SL. Sir2mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci USA 2004; 101: 15998-6003.
47. Sauve AA, Wolberger C, Schramm VL, Boeke JD. The biochemistry of sirtuins. Annu Rev Biochem 2006; 75: 435-65.
48. Pucci B, Villanova L, Sansone L, et al. Sirtuins: the molecular basis of beneficial effects of physical activity. Intern Emerg Med. 2013; 8: 23-5.
49. Blander G, Guarente, L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004; 73: 417-35.
50. Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochemical & Biophysical Research Communications. 2000; 273: 793-8.
51. Frankel S, Ziafazeli T, Rogina B. dSir2 and longevity in Drosophila. Exp Gerontol 2011; 46: 391-6.
52. Kaur S, Shivange AV, Roy N. Structural analysis of trypanosomal sirtuin: an insight for selective drug design. Mol Divers 2010; 14: 169-78.
53. North BJ, Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol 2004; 5: 224.
54. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins--novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 2008; 7: 841-53.
55. Vaquero A, Sternglanz R, Reinberg D. NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs. Oncogene 2007; 26: 5505-20.
56. Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L, Sternglanz R. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci USA 2000; 97: 5807-11.
57. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403: 795-800.
58. Smith JS, Brachmann CB, Celic I, et al. A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc Natl Acad Sci USA 2000; 97: 6658-66.
59. Haigis MC, Mostoslavsky R, Haigis KM, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 2006; 126: 941-54.
60. Liszt G, Ford E, Kurtev M, Guarente L. Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J Biol Chem 2005; 280: 21313-20.
61. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149-59.
62. Tanner KG, Landry J, Sternglanz R, Denu JM. Silent information regulator 2 family of NADdependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc Natl Acad Sci USA 2000; 97: 14178-82.
63. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 2000; 14: 1021-6.
64. Fabrizio P, Gattazzo C, Battistella L, et al. Sir2 blocks extreme life-span extension. Cell 2005; 123: 655-67.
65. Rogina B, Helfand SL. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci USA 2004; 101: 15998-6003.
66. Bauer JH, Morris SNS, Chang C, Flatt T, Wood JG, Helfand SL. dSir2 and Dmp53 interact to mediate aspects of CR-dependent life span extension in D. melanogaster. Aging 2009; 1: 38-49.
67. Rogina B, Helfand SL. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci USA 2004; 101: 15998-6003.
68. Kanfi Y, Naiman S, Amir G, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature 2012; 483: 218-21.
69. Minor RK, Allard JS, Younts CM, Ward TM, de Cabo R. Dietary interventions to extend life span and health span based on calorie restriction. J Gerontol A Biol Sci Med Sci 2010; 65: 695-703.
70. Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae Science 2000; 289: 2126-8.
71. Lin SJ, Kaeberlein M, Andalis AA, et al. Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration. Nature 2002; 418: 344-8.
72. Loeb J, Northrop JH. On the influence of food and temperature upon the duration of life. J Biol Chem 1917; 32: 103-21.
73. Comfort A. Effect of delayed and resumed growth on the longevity of a fish (Lebistes reticulatus, Peters) in captivity. Gerontologia 1963; 49: 150-5.
74. Austad SN. Life extension by dietary restriction in the bowl and doily spider, Frontinella pyramitela Exp Gerontol 1989; 24: 83-9.
75. Rogina B, Helfand SL. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci 2004; 101: 15998-6003.
76. Wang Y, Tissenbaum HA. Overlapping and distinct functions for a Caenorhabditis elegans SIR2 and DAF-16/ FOXO. Mech Ageing Dev 2006; 127: 48-56.
77. Kaeberlein M, McVey M, Guarente L. The SIR2/ 3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes & Dev 1999; 13: 2570-80.
78. Kaeberlein M, Kirkland KT, Fields S, Kennedy BK. Sir2-independent life span extension by calorie restriction in yeast. PLoS Biol 2004; 2: E296.
79. Parashar V, Rogina B. dSir2 mediates the increased spontaneous physical activity in flies on calorie restriction. Aging (Albany NY). 2009; 1: 529-41.
80. Bauer JH, Morris SN, Chang C, Flatt T, Wood JG, Helfand SL. dSir2 and Dmp53 interact to mediate aspects of CR-dependent lifespan extension in D. melanogaster. Aging (Albany NY). 2009; 1: 38-48.
81. Han C, Someya S. Maintaining good hearing: Calorie restriction, Sirt3, and glutathione. Exp Gerontol 2013; pii: S0531-5565: 00045-4.
82. Wolters S, Schumacher B. Genome maintenance and transcription integrity in aging and disease. Front Genet 2013; 4: 19.
83. Schumacher B, Garinis GA, Hoeijmakers JHJ. Age to survive: DNA damage and aging. Trends Genet 2008; 24: 77-85.
84. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460: 587-91.
85. Guarente L, Picard F. Calorie restriction-the SIR2 connection. Cell 2005; 120: 473-82.
86. Denu JM. Linking chromatin function with metabolic networks: Sir2 family of NAD1-dependent deacetylases. Trends Biochem Sci 2003; 28: 41-8.
87. Yuan Z, Zhang X, Sengupta N, Lane WS, Seto E. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell 2007; 27: 149-62.
88. Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008; 14: 312-23.
89. Jia G, Su L, Singhal S, Liu X. Emerging roles of SIRT6 on telomere maintenance, DNA repair, metabolism and mammalian aging. Mol Cell Biochem. 2012; 364: 345-50.
90. Barzilai N, Banerjee S, Hawkins M, Chen W, Rossetti L. Caloric restriction reverses hepatic insulin resistance in aging rats by decreasing visceral fat. J Clin Invest 1998; 101: 1353-61.
91. Dhahbi JM, Mote PL, Wingo J, Rowley BC, Cao SX, Walford RL, Spindler SR. Caloric restriction alters the feeding response of key metabolic enzyme genes. Mech Ageing Dev 2001; 122: 1033-48.
92. Rivka B. Regulation of carbohydrate metabolism. Boca Raton, Fla: CRC Press, c1985.
93. Moynihan KA, Grimm AA, Plueger MM, et al. Increased dosage of mammalian Sir2 in pancreatic ß cells enhances glucose-stimulated insulin secretion in mice. Cell Metab 2005; 2: 105-17.
94. Bordone L, Motta MC, Picard F, et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic ß cells. PLoS Biol 2006; 4: 31.
95. Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1a. J Biol Chem 2005; 280: 16456-60.
96. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nature 2005; 434: 113-8.
97. Xue L, Xu F, Meng L, et al. Acetylation-dependent regulation of mitochondrial ALDH2 activation by SIRT3 mediates acute ethanol-induced eNOS activation. FEBS Lett 2012; 586: 137-42.
98. Newman JC, He W, Verdin E. Mitochondrial protein acylation and intermediary metabolism: regulation by sirtuins and implications for metabolic disease. J Biol Chem 2012; 287: 42436-43.
99. Haigis MC, Mostoslavsky R, Haigis KM, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 2006; 126: 941-54.
100. Nakagawa T, Lomb DJ, Haigis MC, Guarente L. SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 2009; 137: 560-70.
101. Ogura M, Nakamura Y, Tanaka D, et al. Overexpression of SIRT5 confirms its involvement in deacetylation and activation of carbamoyl phosphate synthetase 1. Biochem Biophys Res Commun 2010; 393: 73-8.
102. Chakraborty C. Biochemical and molecular basis of insulin resistance. Curr Protein Pept Sci 2006; 7: 113-21.
103. Chakraborty C, Roy SS, Hsu MJ, Agoramoorthy G. Landscape mapping of functional proteins in insulin signal transduction and insulin resistance: a network-based protein-protein interaction analysis. PLoS One 2011; 6: e16388.
104. Sun C, Zhang F, Ge X, et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007; 6: 307-19.
105. Deng CX. SIRT1, is it a tumor promoter or tumor suppressor? Int. J. Biol. Sci 2009; 5: 147-52.
106. Zhu H, Guo Q, Mattson MP. Dietary restriction protects hippocampal neurons against the death-promoting action of a presenilin-1 mutation. Brain Res 1999; 842: 224-9.
107. Patel NV, Gordon MN, Connor KE, et al. Caloric restriction attenuates Aß-deposition in Alzheimer transgenic models. Neurobiol. Aging 2005; 26: 995-1000.
108. Duan W, Mattson MP. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J Neurosci Res 1999; 57: 195-206.
109. Haigis MC, Guarente LP. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006; 20: 2913-21.
110. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Ann Review Pathol. 2010; 5: 253-95.
111. Donmez G, Guarente L. Aging and disease: connections to sirtuins. Aging Cell 2010; 9: 285-90.
112. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 2010; 5: 253-95.
113. Wang Y, Xu C, Liang Y, Vanhoutte PM. SIRT1 in metabolic syndrome: where to target matters. Pharmacol Ther 2012; 136: 305-18.
114. Zhao Y, Luo P, Guo Q, et al. Interactions between SIRT1 and MAPK/ERK regulate neuronal apoptosis induced by traumatic brain injury in vitro and in vivo. Exp Neurol 2012; 237: 489-98.
115. Donmez G, Outeiro TF. SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med 2013; 5: 344-52.
116. Li XH, Chen C, Tu Y, et al. Sirt1 Promotes Axonogenesis by Deacetylation of Akt and Inactivation of GSK3. Mol Neurobiol 2013;[Epub ahead of print].
117. Chen HZ, Wan YZ, Liu DP. Cross-talk between SIRT1 and p66Shc in vascular diseases. Trends Cardiovasc Med 2013; pii: S1050-1738: 00017-0.
118. Breitenstein A, Wyss CA, Spescha RD, et al. Peripheral blood monocyte Sirt1 expression is reduced in patients with coronary artery disease. PLoS One 2013; 8: e53106.
119. Kume S, Kitada M, Kanasaki K, Maegawa H, Koya D. Anti-aging molecule, Sirt1: a novel therapeutic target for diabetic nephropathy. Arch Pharm Res 2013; 36: 230-6.
120. Jung YJ, Lee JE, Lee AS, et al. SIRT1 overexpression decreases cisplatin-induced acetylation of NF-κB p65 subunit and cytotoxicity in renal proximal tubule cells. Biochem Biophys Res Commun. 2012 Mar 9; 419: 206-10.
121. Wu L, Zhang Y, Ma X, Zhang N, Qin G. The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats. Mol Biol Rep 2012; 39: 9085-93.
122. Lerrer B, Cohen HY. The guardian: metabolic and tumoursuppressive effects of SIRT6. EMBO J 2013; 32: 7-8.
123. Sebastián C, Zwaans BM, Silberman DM, et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 2012; 151: 1185-99.
124. Bauer I, Grozio A, Lasigliè D, et al. The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J Biol Chem 2012; 287(49): 40924-37.
125. Min L, Ji Y, Bakiri L, et al. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol 2012; 14(11): 1203-11.
126. Khongkow M, Olmos Y, Gong C, et al. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis. 2013 [Epub ahead of print].
127. Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes & Dev 2006; 20: 1075-80.
128. Vakhrusheva O, Smolka C, Gajawada P, et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res 2008; 102: 703-10.
129. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 2003; 11(2): 437-44.
130. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 2005; 16: 4623-35.
131. Imai S, Johnson FB, Marciniak RA, McVey M, Park PU, Guarente L. Sir2: An NAD-dependent histone deacetylase that connects chromatin silencing, metabolism, and aging. Cold Spring Harb Symp Quant Biol 2000; 65: 297-302.
132. He X, Nie H, Hong Y, Sheng C, Xia W, Ying W. SIRT2 activity is required for the survival of C6 glioma cells. Biochem Biophys Res Commun 2012; 417: 468-72.
133. Narayan N, Lee IH, Borenstein R, et al. The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Nature 2012; 492: 199-204.
134. Inoue T, Hiratsuka M, Osaki M, Oshimura M.The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle 2007; 6: 1011-8.
135. Das C, Lucia MS, Hansen KC, Tyler JK. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 2009; 459: 113-7.
136. Rose G, Dato S, Altomare K, et al. Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Exp Gerontol 2003; 38: 1065-70.
137. Alhazzazi TY, Kamarajan P, Joo N, et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2011; 117: 1670-8.
138. Yu X, Zhang L, Yang X, et al. Salvianolic acid A protects the peripheral nerve function in diabetic rats through regulation of the AMPK-PGC1_-Sirt3 axis. Molecules 2012; 17: 11216-28.
139. Jeong SM, Xiao C, Finley LW, et al. SIRT4 Has Tumor-Suppressive Activity and Regulates the Cellular Metabolic Response to DNA Damage by Inhibiting Mitochondrial Glutamine Metabolism. Cancer Cell 2013: pii: S1535-6108: 00078-0.
140. Nasrin N, Wu X, Fortier E, et al. SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle cells. J Biol Chem. 2010; 285: 31995-2002.
141. Chowdari KV, Northup A, Pless L, et al. DNA pooling: a comprehensive, multi-stage association analysis of ACSL6 and SIRT5 polymorphisms in schizophrenia. Genes Brain Behav 2007; 6: 229-39.
142. Gertz M, Steegborn C. Function and regulation of the mitochondrial sirtuin isoform Sirt5 in Mammalia. Biochim Biophys Acta 2010; 1804: 1658-65.
143. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA. Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci USA 2001; 98: 15113-8.
144. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 2001; 276: 38837-43.
145. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450: 712-6.
146. Mai A, Valente S, Meade S, et al. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. J Med Chem 2009; 52: 5496-504.
147. Alcain FJ, Villalba JM. Sirtuin inhibitors. Expert Opin Ther Pat 2009; 19: 283-94.
148. Price NL, Gomes AP, Ling AJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012; 15: 675-90.
149. Kitada M, Kume S, Takeda-Watanabe A, Kanasaki K, Koya D. Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clin Sci (Lond) 2013; 124: 153-64
150. Kitada M, Kume S, Kanasaki K, Takeda-Watanabe A, Koya D. Sirtuins as possible drug targets in type 2 diabetes. Curr Drug Targets 2013[Epub ahead of print].
151. Zhu H, Zhao L, Wang E, et al. The QKI-PLP pathway controls SIRT2 abundance in CNS myelin. Glia 2012; 60: 69-82.
152. Beirowski B, Gustin J, Armour SM, et al. Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling. Proc Natl Acad Sci USA 2011; 108: E952- E961.
153. Jiang W, Wang S, Xiao M, et al. Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol Cell 2011; 43: 33-44.
154. de Oliveira RM, Sarkander J, Kazantsev AG, Outeiro TF. SIRT2 as a Therapeutic Target for Age-Related Disorders. Front Pharmacol 2012; 3: 82.
155. Hirschey MD, Shimazu T, Goetzman E, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010; 464: 121-5.
156. Shi T, Wang F, Stieren E, Tong Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem 2005; 280: 13560-7.
157. Kendrick AA, Choudhury M, Rahman SM, et al. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J 2011; 433: 505-14.
158. Komlos D, Mann KD, Zhuo Y, Ricupero CL, Hart RP, Liu AY, Firestein BL.Glutamate dehydrogenase 1 and SIRT4 regulate glial development. Glia 2013; 61: 394-408.
159. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007; 404: 1-13.
160. Nakagawa T, Guarente L. Urea cycle regulation by mitochondrial sirtuin, SIRT5. Aging (Albany NY) 2009; 1: 578-81.
161. Nakagawa T, Lomb DJ, Haigis MC, Guarente L. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 2009; 137: 560-70.
162. Beauharnois JM, Bolívar BE, Welch JT. Sirtuin 6: a review of biological effects and potential therapeutic properties. Mol Biosyst 2013.[Epub ahead of print].
163. Sebastian C, Du J, Kim R, et al. SIRT6 regulates TNF-α secretion through hydrolysis of long-chain fatty acyl lysine. Nature 2013; 496: 110-3.
164. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov 2012: 11; 443-61.
165. Tsai YC, Greco TM, Boonmee A, Miteva Y, Cristea IM. Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. Mol Cell Proteomics 2012; 11: M111.015156.
166. Barber MF, Michishita-Kioi E, Xi Y, et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 2012; 487: 114-8.